Structure-activity relationships of antineoplastic ring-substituted ether phospholipid derivatives. 2005

Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
Department of Animal and Human Physiology, School of Biology, University of Athens, Panepistimiopolis, 15784, Athens, Greece.

OBJECTIVE Previous studies have shown that alkylphosphocholines (APCs) exhibit strong antineoplastic activity against various tumour cell lines in vitro and in several animal models. The current study was designed to investigate the influence of cycloalkane rings on the antiproliferative activity of APCs against a panel of eight human and animal cell lines (PC3, MCF7, A431, Hela, PC12, U937, K562, CHO). Specifically, we explored the effect of the presence of 4-alkylidenecyclohexyl and cycloalkylidene groups in alkoxyethyl and alkoxyphosphodiester ether lipids, respectively. In addition, the haemolytic activity of the new ring-substituted ether phospholipids (EP) was evaluated. METHODS Cells were exposed to various concentrations of the compounds for 72 h. The cytotoxicity was determined with the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] dye reduction assay. Similarly, red blood cells were distributed in 96-well microplates and treated with the test compounds at concentrations ranging from 100 to 6.25 microM for 1 h. After centrifugation, the absorbance of the supernatants was measured at 550 nm. RESULTS The majority of the compounds tested exhibited significant cytotoxic activity which depended on both the ring size and position with respect to the phosphate moiety, as well as the head group. Among the cycloalkylidene series the 11-adamantylideneundecyl-substituted N-methylmorpholino EP 13 was the most potent and exhibited broad-spectrum anticancer activity comparable to or superior to that of hexadecylphosphocholine (HePC). All the adamantylidene-substituted EPs were nonhaemolytic (concentration that exhibits 50% haemolytic activity, HC(50), >100 microM). Furthermore, the cyclohexylidene-substituted analogues were more potent against the cell lines tested, with the exception of U937 and K562, than the cyclodecapentylidene-substituted compounds. Hydrogenation of the double bond in the cycloalkylidene-substituted EPs (compounds 14 and 15) resulted in improvement of anticancer activity. Among the 2-(4-alkylidenecyclohexyloxy)ethyl EPs, 2-(4-hexadylidenecyclohexyloxy)ethyl phosphocholine (22) possessed the highest broad-spectrum cytotoxic activity than all the other analogues of this series and was nonhaemolytic (HC(50) >100 microM). In general, the 2-(4-alkylidenecyclohexyloxy)ethyl-substituted EPs were more active against the more resistant cell lines U937, K562 and CHO than HePC. CONCLUSIONS The presence of cycloalkane rings in the lipid portion of APCs reduces haemolytic effects compared to HePC and in several analogues results in improved antineoplastic activity.

UI MeSH Term Description Entries
D008297 Male Males
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010742 Phospholipid Ethers Phospholipids which have an alcohol moiety in ethereal linkage with a saturated or unsaturated aliphatic alcohol. They are usually derivatives of phosphoglycerols or phosphatidates. The other two alcohol groups of the glycerol backbone are usually in ester linkage. These compounds are widely distributed in animal tissues. Ether Phosphatidates,Ether Phospholipids,Glycerol Phosphate Ethers,Glycerophosphate Ethers,1-Alkyl-2-Acylphosphatidates,1 Alkyl 2 Acylphosphatidates,Ethers, Glycerol Phosphate,Ethers, Glycerophosphate,Ethers, Phospholipid,Phosphate Ethers, Glycerol,Phosphatidates, Ether,Phospholipids, Ether
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D003412 Cricetulus A genus of the family Muridae consisting of eleven species. C. migratorius, the grey or Armenian hamster, and C. griseus, the Chinese hamster, are the two species used in biomedical research. Hamsters, Armenian,Hamsters, Chinese,Hamsters, Grey,Armenian Hamster,Armenian Hamsters,Chinese Hamster,Chinese Hamsters,Grey Hamster,Grey Hamsters,Hamster, Armenian,Hamster, Chinese,Hamster, Grey
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006461 Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity. Haemolysis,Extravascular Hemolysis,Intravascular Hemolysis,Extravascular Hemolyses,Haemolyses,Hemolyses, Extravascular,Hemolyses, Intravascular,Hemolysis, Extravascular,Hemolysis, Intravascular,Intravascular Hemolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
February 2007, Bioorganic & medicinal chemistry,
Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
April 1982, Archiv der Pharmazie,
Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
September 1984, Archives internationales de pharmacodynamie et de therapie,
Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
April 1986, Lipids,
Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
September 1977, The Journal of antibiotics,
Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
April 1957, The Journal of pharmacology and experimental therapeutics,
Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
January 1978, NIDA research monograph,
Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
July 1986, Yao xue xue bao = Acta pharmaceutica Sinica,
Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
September 1975, Archiv der Pharmazie,
Panagiota Papazafiri, and Nicolaos Avlonitis, and Panagiotis Angelou, and Theodora Calogeropoulou, and Maria Koufaki, and Efi Scoulica, and Irene Fragiadaki
February 2008, Journal of medicinal chemistry,
Copied contents to your clipboard!